569 related articles for article (PubMed ID: 9925787)
1. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
2. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
Norledge BV; Petrovan RJ; Ruf W; Olson AJ
Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
[TBL] [Abstract][Full Text] [Related]
3. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla).
Kemball-Cook G; Johnson DJ; Tuddenham EG; Harlos K
J Struct Biol; 1999 Oct; 127(3):213-23. PubMed ID: 10544046
[TBL] [Abstract][Full Text] [Related]
5. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
6. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.
Banner DW; D'Arcy A; Chène C; Winkler FK; Guha A; Konigsberg WH; Nemerson Y; Kirchhofer D
Nature; 1996 Mar; 380(6569):41-6. PubMed ID: 8598903
[TBL] [Abstract][Full Text] [Related]
7. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
Jin J; Perera L; Stafford D; Pedersen L
J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor.
Carlsson K; Persson E; Carlsson U; Svensson M
Biochem Biophys Res Commun; 2006 Oct; 349(3):1111-6. PubMed ID: 16970919
[TBL] [Abstract][Full Text] [Related]
9. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
10. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
11. Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa.
Krishnan R; Kotian PL; Chand P; Bantia S; Rowland S; Babu YS
Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):689-97. PubMed ID: 17505107
[TBL] [Abstract][Full Text] [Related]
12. Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.
Huang H; Norledge BV; Liu C; Olson AJ; Edgington TS
Biochemistry; 2003 Sep; 42(36):10619-26. PubMed ID: 12962485
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
[TBL] [Abstract][Full Text] [Related]
14. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
[TBL] [Abstract][Full Text] [Related]
15. Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity.
Kelley RF; Yang J; Eigenbrot C; Moran P; Peek M; Lipari MT; Kirchhofer D
Biochemistry; 2004 Feb; 43(5):1223-9. PubMed ID: 14756558
[TBL] [Abstract][Full Text] [Related]
16. Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity.
Jin J; Chang J; Chang JY; Kelley RF; Stafford DW; Straight DL
Biochemistry; 1999 Jan; 38(4):1185-92. PubMed ID: 9930978
[TBL] [Abstract][Full Text] [Related]
17. The lipoprotein-associated coagulation inhibitor.
Broze GJ; Girard TJ; Novotny WF
Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
[TBL] [Abstract][Full Text] [Related]
18. Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa.
Persson E; Olsen OH
FEBS J; 2009 Jun; 276(11):3099-109. PubMed ID: 19490111
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.
Stassen JM; Lambeir AM; Matthyssens G; Ripka WC; Nyström A; Sixma JJ; Vermylen J
Thromb Haemost; 1995 Aug; 74(2):646-54. PubMed ID: 8585001
[TBL] [Abstract][Full Text] [Related]
20. Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain.
Ruf W; Shobe J; Rao SM; Dickinson CD; Olson A; Edgington TS
Biochemistry; 1999 Feb; 38(7):1957-66. PubMed ID: 10026279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
